Compounds > mdl29,951
Page last updated: 2024-12-08

mdl29,951

Cross-References

ID SourceID
PubMed CID446916
CHEMBL ID31344
SCHEMBL ID8463078
MeSH IDM000594717

Synonyms (34)

Synonym
BRD-K59753853-001-01-5
IDI1_018404
BPBIO1_001266
OPREA1_596892
BIOMOL-NT_000207
1LEV
DB04175
3-(2-carboxy-ethyl)-4,6-dichloro-1h-indole-2-carboxylic acid
mdl-29951
NCGC00163269-01
MAYBRIDGE3_007017
HMS1450O21
mdl 29951
CHEMBL31344 ,
3-(2-carboxyethyl)-4,6-dichloro-1h-indole-2-carboxylic acid
bdbm50004952
CS-1958
HY-16312
130798-51-5
2-carboxy-4,6-dichloro-1h-indole-3-propanoic acid
SCHEMBL8463078
AC-35287
HMS3604I17
AKOS026750250
EX-A270
CCG-251602
AS-68689
1h-indole-3-propanoic acid, 2-carboxy-4,6-dichloro-
mfcd00897722
NCGC00163269-02
FT-0700161
Q27095008
BCP08592
A13729

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (21)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Fructose-1,6-bisphosphataseSus scrofa (pig)IC50 (µMol)2.50002.50002.50002.5000AID977608
Fructose-1,6-bisphosphatase 1Homo sapiens (human)IC50 (µMol)2.16670.01002.00979.8000AID1076089; AID1076090; AID1189736
Glutamate receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)273.00000.00011.617910.0000AID92506
Glutamate receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)273.00000.00011.700010.0000AID92506
Glutamate receptor 3Rattus norvegicus (Norway rat)IC50 (µMol)273.00000.00011.700010.0000AID92506
Glutamate receptor 4Rattus norvegicus (Norway rat)IC50 (µMol)273.00000.00011.700010.0000AID92506
Glutamate receptor ionotropic, kainate 1Rattus norvegicus (Norway rat)IC50 (µMol)418.00000.00700.98217.0000AID93726
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)89.59480.00071.600310.0000AID1385402; AID1385403; AID143068; AID145260
Glutamate receptor ionotropic, kainate 2Rattus norvegicus (Norway rat)IC50 (µMol)418.00000.00701.01327.0000AID93726
Glutamate receptor ionotropic, kainate 3Rattus norvegicus (Norway rat)IC50 (µMol)418.00000.00701.01327.0000AID93726
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)119.43670.00071.630610.0000AID1385402; AID1385403; AID145260
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)119.43670.00061.525710.0000AID1385402; AID1385403; AID145260
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)90.25250.00071.747210.0000AID1385402; AID1385403; AID143231; AID145260
Glutamate receptor ionotropic, kainate 4Rattus norvegicus (Norway rat)IC50 (µMol)418.00000.00701.01327.0000AID93726
Uracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)Ki1.99331.21003.03506.5400AID1137663; AID1137664; AID1385418
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)119.43670.00071.741110.0000AID1385402; AID1385403; AID145260
Glutamate receptor ionotropic, kainate 5Rattus norvegicus (Norway rat)IC50 (µMol)418.00000.00701.01327.0000AID93726
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)119.43670.00071.741110.0000AID1385402; AID1385403; AID145260
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)119.43670.00071.741110.0000AID1385402; AID1385403; AID145260
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Uracil nucleotide/cysteinyl leukotriene receptorRattus norvegicus (Norway rat)EC50 (µMol)0.70500.70500.70500.7050AID1385405
Uracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)EC50 (µMol)0.40960.00630.40960.8128AID1339654; AID1339655
Uracil nucleotide/cysteinyl leukotriene receptorMus musculus (house mouse)EC50 (µMol)1.11001.11001.11001.1100AID1385406
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 6-phosphate metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
gluconeogenesisFructose-1,6-bisphosphatase 1Homo sapiens (human)
regulation of gluconeogenesisFructose-1,6-bisphosphatase 1Homo sapiens (human)
dephosphorylationFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of cell growthFructose-1,6-bisphosphatase 1Homo sapiens (human)
response to nutrient levelsFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to insulin stimulusFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of glycolytic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of Ras protein signal transductionFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to magnesium ionFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to cAMPFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to xenobiotic stimulusFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular hyperosmotic salinity responseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular hypotonic salinity responseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to raffinoseFructose-1,6-bisphosphatase 1Homo sapiens (human)
cellular response to phorbol 13-acetate 12-myristateFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 1,6-bisphosphate metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose metabolic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
sucrose biosynthetic processFructose-1,6-bisphosphatase 1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
oligodendrocyte differentiationUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
chemokine-mediated signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
protein bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
AMP bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
fructose 1,6-bisphosphate 1-phosphatase activityFructose-1,6-bisphosphatase 1Homo sapiens (human)
identical protein bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
metal ion bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
monosaccharide bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingFructose-1,6-bisphosphatase 1Homo sapiens (human)
chemokine receptor activityUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
receptor serine/threonine kinase bindingUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
G protein-coupled receptor activityUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytoplasmFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytosolFructose-1,6-bisphosphatase 1Homo sapiens (human)
extracellular exosomeFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytoplasmFructose-1,6-bisphosphatase 1Homo sapiens (human)
cytosolFructose-1,6-bisphosphatase 1Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
plasma membraneUracil nucleotide/cysteinyl leukotriene receptorHomo sapiens (human)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay IDTitleYearJournalArticle
AID132457The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intracerebroventricular), for 5 min drug pretreatment time1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1137663Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes after 60 mins by competition binding assay2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID143765Selectivity ratio for CPP and gly NMDA binding1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID1385406Agonist activity at mouse GPR17 expressed in HEK293 cells assessed as induction of intracellular calcium mobilization by calcium 5-dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID71953Inhibitory activity against Fructose-1,6-bisphosphatase (F16BPase) in porcine kidney2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
AID234200Ratio of the inhibitory activity against [3H]-CCP for rat cortical and hippocampal membrane glutamate binding site to [3H]glycine for rat cortical and hippocampal membrane binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1385417Selectivity ratio of EC50 for mouse GPR17 expressed in HEK293 cells to EC50 for human GPR17 expressed in human 1321N1 cells2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID71952Inhibitory activity against Fructose-1,6-bisphosphatase (F16BPase) in human liver2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
AID132459The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intravenous), for 5 min drug pretreatment time1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1385405Agonist activity at rat GPR17 expressed in HEK293 cells assessed as induction of intracellular calcium mobilization by calcium 5-dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID145260In vitro inhibition of [3H]glycine at NMDA receptor1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID684832Inhibition of human recombinant FBPase using fructose-1,6-biphosphate as substrate incubated for 3 mins prior to substrate addition by spectrophotometric analysis2012European journal of medicinal chemistry, Oct, Volume: 56Ligand-based designing, in silico screening, and biological evaluation of new potent fructose-1,6-bisphosphatase (FBPase) inhibitors.
AID1385416Selectivity ratio of EC50 for rat GPR17 expressed in HEK293 cells to EC50 for human GPR17 expressed in human 1321N1 cells2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID1385403Displacement of [3H]CCP from NMDA receptor glutamate binding site in rat cortical and hippocampal membranes2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID1385413Agonist activity at human P2Y12 receptor transfected in CHO cells assessed as induction of beta-arrestin translocation2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID1137662Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes assessed as dissociation half life at 100 uM treated after 1 hr incubation with radioligand by liquid scintillation counting2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID1385411Agonist activity at human P2Y4 receptor transfected in human 1321N1 cells assessed as induction of calcium mobilization after 30 mins in presence of UTP by fluo-4 dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID1137661Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes assessed as association half life at 100 uM by liquid scintillation counting2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID227647Activity was determined by inhibition of glutamate stimulated accumulation of cyclic GMP in neonatal rat cerebral slices.1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID1385402Displacement of [3H]glycine from NMDA receptor in rat cortical and hippocampal membranes2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID132458The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid seizure model (intraperitoneal), for 2 hr drug pretreatment time1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID131549Protection from audiogenic seizure in the DBA/2 mouse 30 min after intraperitoneal administration1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.
AID92506The compound was evaluated in vivo for the competitive binding against [3H]-Ionotropic glutamate receptor AMPA for rat cortical and hippocampal membrane glutamate binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1385409Agonist activity at human P2Y1 receptor transfected in human 1321N1 cells assessed as induction of calcium mobilization after 30 mins in presence of ADP by fluo-4 dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID186995Blockade of NMDA-induced depolarizations on rat cortical slices1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.
AID143231Compound was evaluated for in vitro inhibition of cGMP cerebellar slice at NMDA receptor.1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID1137664Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes after 60 mins by homologous competition binding assay in presence of pranlukast2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID71955Inhibitory activity against Fructose-1,6-bisphosphatase (F16BPase) in rabbit liver2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
AID1076089Inhibition of human recombinant FBPase expressed in Escherichia coli BL21(DE3) by phosphoglucose isomerase and glucose-6-phosphate dehydrogenase coupled assay2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
AID1189736Inhibition of human liver FBPase expressed in Escherichia coli BL21(DE3) Rosetta cells assessed as reduction of NADP+ to NADPH by phosphoglucose isomerase and glucose-6-phosphate dehydrogenase coupling based spectrophotometry2015European journal of medicinal chemistry, Jan-27, Volume: 90Discovery of novel indole derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
AID1385412Agonist activity at human P2Y6 receptor transfected in human 1321N1 cells assessed as induction of calcium mobilization after 30 mins in presence of UDP by fluo-4 dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID143618Ability to compete with [3H]glycine for strychnine-insensitive binding sites on rat cortical and hippocampal membrane1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID112660In vivo antagonist activity against seizures elicited by audiogenic administered icv in mice1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID143610Inhibition of binding of [3H]glycine to N-methyl-D-aspartate glutamate receptor 1 from crude synaptic membranes prepared from adult rat cerebral cortex.1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
(E)-3-(2-(N-phenylcarbamoyl)vinyl)pyrrole-2-carboxylic acid derivatives. A novel class of glycine site antagonists.
AID1385414Agonist activity at human P2Y14 receptor transfected in CHO cells assessed as induction of beta-arrestin translocation2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID1385418Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO cell membranes after 60 mins by liquid scintillation counting2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID143068Inhibition of the binding of [3H]L-689,560 ([3H]-4) to the strychnine-insensitive glycine site on rat brain membranes1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
3'-(Arylmethyl)- and 3'-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor.
AID1385410Agonist activity at human P2Y2 receptor transfected in human 1321N1 cells assessed as induction of calcium mobilization after 30 mins in presence of UTP by fluo-4 dye based assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
3-(2-Carboxyethyl)indole-2-carboxylic Acid Derivatives: Structural Requirements and Properties of Potent Agonists of the Orphan G Protein-Coupled Receptor GPR17.
AID132456The compound was evaluated in vivo for the anticonvulsant activity in quinolinic acid + probenecid seizure model (intravenous), for 5 min drug pretreatment time1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID132454The compound was evaluated in vivo for the anticonvulsant activity in audiogenic seizure model (intraperitoneal), for 2 hr drug pretreatment time1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID71956Inhibitory activity against Fructose-1,6-bisphosphatase (F16BPase) in rat liver2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
AID143472Activity against rat cortical and hippocampal membrane strychnine-insensitive N-methyl-D-aspartate glutamate receptor 1 using [3H]-gly1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID143781Activity against rat cortical and hippocampal membrane N-methyl-D-aspartate glutamate receptor 1/2A/2B/2C/2D using [3H]CPP1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
3-(2-carboxyindol-3-yl)propionic acid derivatives: antagonists of the strychnine-insensitive glycine receptor associated with the N-methyl-D-aspartate receptor complex.
AID112661In vivo antagonist activity against seizures elicited by audiogenic administered intra peritoneally in mice1994Journal of medicinal chemistry, Nov-25, Volume: 37, Issue:24
The glycine site on the NMDA receptor: structure-activity relationships and therapeutic potential.
AID143790Ability to compete with [3H]CCP for rat cortical and hippocampal membrane glutamate binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID93726The compound was evaluated in vivo for the competitive binding against [3H]kainate for rat cortical and hippocampal membrane glutamate binding site.1992Journal of medicinal chemistry, May-15, Volume: 35, Issue:10
3-(2-Carboxyindol-3-yl)propionic acid-based antagonists of the N-methyl-D-aspartic acid receptor associated glycine binding site.
AID1076090Inhibition of FBPase (unknown origin)2014Bioorganic & medicinal chemistry, Mar-15, Volume: 22, Issue:6
Design, synthesis and biological evaluation of 7-nitro-1H-indole-2-carboxylic acid derivatives as allosteric inhibitors of fructose-1,6-bisphosphatase.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2003Bioorganic & medicinal chemistry letters, Jun-16, Volume: 13, Issue:12
3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (33.33)18.2507
2000's1 (6.67)29.6817
2010's7 (46.67)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
1-aminocyclopropane-1-carboxylic acid
1-aminocyclopropanecarboxylic acid : A non-proteinogenic alpha-amino acid consisting of cyclopropane having amino and carboxy substituents both at the 1-position.		3.0810amino acid zwitterion;
monocarboxylic acid;
non-proteinogenic alpha-amino acid		ethylene releasers;
plant metabolite
glycine
[no description available]		3.0810alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
5,7-dichlorokynurenic acid
5,7-dichlorokynurenic acid: potent antagonist at the N-methyl-D-aspartate receptor-associated glycine binding site		3.7730quinolines
hydroxyindoleacetic acid
(5-hydroxyindol-3-yl)acetic acid : A member of the class of indole-3-acetic acids that is indole-3-acetic acid substituted by a hydroxy group at C-5.		2.1710indole-3-acetic acidsdrug metabolite;
human metabolite;
mouse metabolite
6,7-dichloroquinoxaline-2,3-dione
[no description available]		3.0810quinoxaline derivative
7-chlorokynurenic acid
7-chlorokynurenic acid: selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex; structure given in first source. 7-chlorokynurenic acid : A quinolinemonocarboxylic acid that is quinaldic acid which is substituted by a hydroxy group at position 4 and by a chlorine at position 7. It is a potent NMDA glutamate receptor antagonist which antagonizes the strychnine-insensitive glycine site of the NMDA receptor. It also prevents neurodegeneration produced by quinolinic acid.		3.4820organochlorine compound;
quinolinemonocarboxylic acid		neuroprotective agent;
NMDA receptor antagonist
rtki cpd
[no description available]		2.0710aromatic ether;
monochlorobenzenes;
quinazolines		antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		2.1710aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
kynurenic acid
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.. kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.		3.7730monohydroxyquinoline;
quinolinemonocarboxylic acid		G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite
pd 153035
4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.		2.0710aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound		EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		2.110chromones
rizatriptan
rizatriptan: structure given in first source; RN given refers to benzoate		2.1710tryptaminesanti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		2.110adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
uridine diphosphate
Uridine Diphosphate: A uracil nucleotide containing a pyrophosphate group esterified to C5 of the sugar moiety.		2.110pyrimidine ribonucleoside 5'-diphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
adenosine monophosphate
Adenosine Monophosphate: Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.		2.7830adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate		adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
uridine triphosphate
Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.		2.110pyrimidine ribonucleoside 5'-triphosphate;
uridine 5'-phosphate		Escherichia coli metabolite;
mouse metabolite
cycloserine
Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).		3.08104-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion		antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist
tryptophan
Tryptophan: An essential amino acid that is necessary for normal growth in infants and for NITROGEN balance in adults. It is a precursor of INDOLE ALKALOIDS in plants. It is a precursor of SEROTONIN (hence its use as an antidepressant and sleep aid). It can be a precursor to NIACIN, albeit inefficiently, in mammals.. tryptophan : An alpha-amino acid that is alanine bearing an indol-3-yl substituent at position 3.		2.1710erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan		antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
uridine diphosphate glucose
Uridine Diphosphate Glucose: A key intermediate in carbohydrate metabolism. Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid. Also serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids.. UDP-alpha-D-glucose : The alpha-anomer of UDP-alpha-D-glucose. It is used in nucleotide sugars metabolism.		2.110UDP-D-glucosefundamental metabolite
2,3-dihydroxyquinoxaline
2,3-dihydroxyquinoxaline: fluorescent oxalic acid deriv.		3.0810
D-serine
[no description available]		3.0810D-alpha-amino acid;
serine zwitterion;
serine		Escherichia coli metabolite;
human metabolite;
NMDA receptor agonist
indole-2-carboxylic acid
[no description available]		2.3820indolyl carboxylic acid
1-aminocyclobutanecarboxylic acid
1-aminocyclobutanecarboxylic acid: RN given refers to unlabeled cpd		3.0810L-alpha-amino acid
3-(2-carboxyindol-3-yl)propionic acid
3-(2-carboxyindol-3-yl)propionic acid: structure given in first source; NMDA antagonist		2.6930
rpr 104632
RPR 104632: structure given in first source		3.0810
6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid
6,7-dichloro-3-hydroxy-2-quinoxalinecarboxylic acid: antagonist of N-methyl-D-aspartic acid and kainate receptors; structure given in first source		3.0810quinoxaline derivative
7-chloro-thiokynurenate
7-chlorothiokynurenic acid: glycine site antagonist of NMDA receptor		3.0810
fg 9041
FG 9041: structure given in first source		3.0810quinoxaline derivative
montelukast
montelukast: a leukotriene D4 receptor antagonist		2.110aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
licostinel
licostinel: a glycine site NMDA receptor antagonist; structure given in first source		3.0810
gavestinel
[no description available]		2.4320
l 689560
[no description available]		3.7830quinolines
N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine
[no description available]		2.0710quinazolines
l 701324
L 701324: a glycine/NMDA receptor antagonist		3.7830quinolines
7-chloro-3-[cyclopropyl(oxo)methyl]-4-hydroxy-1H-quinolin-2-one
[no description available]		3.0810hydroxyquinoline;
quinolone
mdl 104653
3-phenyl-4-hydroxy-7-chloroquinolin-2(1H)-one: an NMDA/glycine site antagonist; structure given in first source		1.9810
9-beta-d-arabinofuranosylguanosine 5'-triphosphate
[no description available]		2.110
ConditionIndicatedRelationship StrengthStudiesTrials
Absence Seizure
[description not available]		02.3920
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.3920
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310
Anaplastic Astrocytoma
[description not available]		02.1710
Astrocytoma
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)		02.1710
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
chemdatabank.com